Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

MEMPHASYS LIMITED. Board/Management Information 2008

Aug 3, 2008

65314_rns_2008-08-03_9c9abb97-29cb-4142-aaf7-e64c80c76ea8.pdf

Board/Management Information

Open in viewer

Opens in your device viewer

==> picture [173 x 57] intentionally omitted <==

FOR IMMEDIATE RELEASE

NuSep Director Resignation

SYDNEY, AUSTRALIA – 4 August, 2008 – NuSep (ASX: NSP) wishes to advise the market that Dr Choon Lee has resigned as a Director of NuSep.

The Company would like to thank Dr Lee for his contribution to the Board over the last two years and wishes him well in his future endeavours.

Appendix 3Z is attached.

About NuSep

NuSep (ASX: NSP) is a publicly listed life sciences company that sells products into the global bioseparations market. The company has offices in both Sydney, Australia and Atlanta, USA.

With a 30 year heritage in biological separations, NuSep has forged a world class reputation for its innovative yet simple biological separation techniques including the world’s first IVF sperm separation device. In short NuSep has redefined the BioSeparations market through innovation and simplification.

NuSep’s world renowned research team has developed an extensive portfolio of patented products. In all, NuSep currently manufactures, distributes and sells 55 products to customers in the USA, Europe, Asia and Australia.

NuSep Products:

==> picture [13 x 10] intentionally omitted <==

==> picture [13 x 10] intentionally omitted <==

==> picture [13 x 10] intentionally omitted <==

  • Gels – NuSep offers two precast gel ranges: iGels, innovative gels including long life gels with a 2 year shelf life: and NuBlu, high quality gels at an everyday price.

  • Separation Instruments – NuSep has developed two unique biological separation instruments. The first instrument released in February 2008 can separate biological samples into 8 fractions for use in the proteomic market. The second instrument separates sperm for fertility treatments such as IVF and is presently undergoing clinical trials and is supported by a $2.2m AusIndustry Commercial Ready Grant.

  • Biological Products – NuSep supplies research grade biological products manufactured using its unique separation technologies. These products include human IgG and Albumin.

For more information about NuSep please visit the company’s website www.NuSep.com

Contact: Prakash Patel Chief Financial Officer & Company Secretary +61 2 8977 9000 [email protected]

NuSep Ltd 22 Rodborough Rd Frenchs Forest NSW 2086

Postal Address P.O. Box 6126 Frenchs Forest NSW 2086

Contact Details Telephone +61 2 8977 9000 Facsimile +61 2 8977 9099

Email [email protected] Web www.nusep.com ABN 33 120 047 556

Appendix 3Z Final Director’s Interest Notice

Rule 3.19A.3

Appendix 3Z

Final Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001.

Name of entity NuSep Ltd (NSP) ABN 33 120 047 556

We (the entity) give ASX the following information under listing rule 3.19A.3 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of director Dr Choon Lee
Date of last notice 20 February 2008
Date that director ceased to be director 30 July 2008

Part 1 – Director’s relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Number & class of securities

979,800 ordinary shares

  • See chapter 19 for defined terms.

Appendix 3Z Page 1

11/3/2002

Appendix 3Z Final Director’s Interest Notice

Part 2 – Director’s relevant interests in securities of which the director is not the registered holder

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of interest
Note: Provide details of the circumstances giving rise to
the relevant interest
Nil
Number & class of securities
Nil

Part 3 – Director’s interests in contracts

Detail of contract Nil
Nature of interest Nil
Name of registered holder
(if issued securities)
Nil
No. and class of securities to
which interest relates
Nil
  • See chapter 19 for defined terms.

Appendix 3Z Page 2

11/3/2002